Announced Mon, 1 Jun · 14:32 IST

With reference to intimation dated May 27, 2026, the Company has completed the acqusition of Lifesenz Cancer Labs Private Limited and has become subsidiary of the Company w.e.f. June 01, 2026.

Listed Co AcquisitionStrategic Transactions View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.7%1-day move
₹404.90
prior close
₹395.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-1.3-1.3-1.0-3.7-3.7-6.9-5.2-11.3-5.9-5.2-6.3
Up moveDown movePending
AI summary

Hemant Surgical Industries Ltd has completed the acquisition of Lifesenz Cancer Research Labs Private Limited, a Mumbai-based cancer research and diagnostics company. The deal was first announced on May 27, 2026, and has now been formally closed on June 01, 2026. With this completion, Lifesenz Cancer Research Labs has become a subsidiary of Hemant Surgical Industries. The filing does not disclose the deal value, share-swap ratio, or stake percentage acquired.

Likely market impact

This expands Hemant Surgical's presence into the cancer diagnostics and research space, potentially diversifying its revenue streams. Without deal financials, investors may await further disclosures to gauge the impact on earnings and balance sheet.